Arana files IND

By Dylan Bushell-Embling
Tuesday, 30 September, 2008

Arana Therapeutics [ASX: AAH] has submitted an IND to the FDA for its candidate ART621 for rheumatoid arthritis.

As part of the IND application, a Phase II dose trial of the anti-TNF drug will be conducted in a multi-centre trial in 200 patients.

Arana expects to begin recruitment for the study later this year, pending approval from the FDA. Quintiles has been named as the contract research manager.

Unhealthy Western diet could accelerate cognitive decline

An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...

Cancer drug enters clinical trials based on a false mechanism

A cancer drug currently being tested in patients appears to have entered clinical trials based on...

Russia insists there is "no plague case" following lab worker death

Russian health authorities say there is no evidence that pneumonic plague played a part in the...

Content from other channels on our network

The roles of the vendor and EPCs in the project bidding process

ARC awards $82.5m for new research hubs and training centres

Industrial electricity costs could halve by sharing infrastructure

Seeq and Applied Computing partner on industrial AI for energy operations

ARENA opens Round 3 of Solar Sunshot with $250m available

AFGC welcomes Domestic Gas Reservation Bill

Beverage facility built to keep the good times rolling

Industries transitioning away from gas, A2EP report released

Six on the shelf: from frozen treats to smoothies & meal kits

58% of food manufacturers report less productivity, research finds

Burnout in health care isn't an 80/20 problem: why a more balanced view is needed and what it means for you and your workplace

A Good Cleaning Schedule: Best Practices for Healthcare Facilities

Conviction and $20K fine follows "serious and prolonged" offending by former podiatrist

Supagas acquires Heeson Medical

Why digital resilience is becoming critical in aged care